Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel.
Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JM, Moskop A, Verneris MR, Myers GD, Hall EM, Karras NA, Bonifant CL, Qayed M, Bakinowski E, Keating A, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen K, Baggott C, Schultz LM, McNerney KO.
Naik S, et al. Among authors: hall em.
Blood Adv. 2025 Jul 21:bloodadvances.2025016824. doi: 10.1182/bloodadvances.2025016824. Online ahead of print.
Blood Adv. 2025.
PMID: 40690779